Literature DB >> 19790232

Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth.

Chih-Rong Shyr1, Meng-Yin Tsai, Shuyuan Yeh, Hong-Yo Kang, Yun-Chao Chang, Pei-Ling Wong, Chao-Cheng Huang, Ko-En Huang, Chawnshang Chang.   

Abstract

BACKGROUND: PAX6, a transcription factor, has currently been suggested to function as a tumor suppressor in glioblastoma and to act as an early differentiation marker for neuroendocrine cells. The androgen receptor (AR) plays a pivotal role in prostate cancer development and progression due to its transcriptional activity in regulating genes involved in cell growth, differentiation, and apoptosis. To determine the role of PAX6 in prostate cancer, we investigated whether PAX6 interacts with AR to affect prostate cancer development.
METHODS: We used immunostaining, RT-PCR, and Western blotting assays to show the expression status of PAX6 in prostate tissue and human prostate cancer cell lines. The role of PAX6 in cell growth and colony regeneration potential of LNCaP cells were evaluated by MTT assay and soft agar assay with PAX6-overexpressed LNCaP cells. Mammalian two-hybrid and co-immunoprecipitation (Co-IP) assays were used to demonstrate the interaction between PAX6 and AR. Reporter gene and Q-RT-PCR assays were performed to determine the effects of PAX6 on the function of AR.
RESULTS: In prostate cancer tissues, PAX6 expression was stronger in normal epithelial cells than cancer cells, and decreased in LNCaP cells compared to that of DU145 and PC3 cells. Enforced expression of PAX6 suppressed the cell growth of LNCaP cells and also inhibited the colony formation of LNCaP cells. PAX 6 interacted with AR and repressed its transcriptional activity. PAX6 overexpression decreased the expression of androgen target gene PSA in LNCaP cells.
CONCLUSIONS: In this study, we found that PAX6 may act as a prostate cancer repressor by interacting with AR and repressing the transcriptional activity and target gene expression of AR to regulate cell growth and regeneration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19790232      PMCID: PMC3729259          DOI: 10.1002/pros.21052

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  43 in total

1.  Pax6 is essential for establishing ventral-dorsal cell boundaries in pituitary gland development.

Authors:  C Kioussi; S O'Connell; L St-Onge; M Treier; A S Gleiberman; P Gruss; M G Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

Review 2.  Pax genes and the differentiation of hormone-producing endocrine cells in the pancreas.

Authors:  C Dohrmann; P Gruss; L Lemaire
Journal:  Mech Dev       Date:  2000-03-15       Impact factor: 1.882

Review 3.  A PANorama of PAX genes in cancer and development.

Authors:  Ewan J D Robson; Shu-Jie He; Michael R Eccles
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

4.  PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene.

Authors:  Debra A Mayes; Yuanjie Hu; Yue Teng; Eric Siegel; Xiaosong Wu; Kishori Panda; Fang Tan; W K Alfred Yung; Yi-Hong Zhou
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

Review 5.  Prostate cancer: molecular biology of early progression to androgen independence.

Authors:  M D Sadar; M Hussain; N Bruchovsky
Journal:  Endocr Relat Cancer       Date:  1999-12       Impact factor: 5.678

Review 6.  Cellular and molecular control of neurogenesis in the mammalian telencephalon.

Authors:  François Guillemot
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

7.  Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses.

Authors:  E Schoenmakers; G Verrijdt; B Peeters; G Verhoeven; W Rombauts; F Claessens
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

8.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

9.  Methylation of the TPEF- and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours.

Authors:  Olaf J C Hellwinkel; Merab Kedia; Hendrik Isbarn; Lars Budäus; Martin G Friedrich
Journal:  BJU Int       Date:  2007-12-07       Impact factor: 5.588

10.  Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor.

Authors:  Yan Dai; Duyen Ngo; Lora W Forman; David C Qin; Johanna Jacob; Douglas V Faller
Journal:  Mol Endocrinol       Date:  2007-05-15
View more
  25 in total

1.  [Construction of a lentiviral vector carrying short?hairpin RNA targeting PAX6 and its effect on proliferation of glioma U251 cells in vitro].

Authors:  Xiao-Hong Liao; Wei-Lan Yin; Fang Wang; Li-Xiang Wu; Bai-Sheng Huang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-12-20

2.  Pax6 localizes to chromatin-rich territories and displays a slow nuclear mobility altered by disease mutations.

Authors:  Julianne Elvenes; Eva Sjøttem; Turid Holm; Geir Bjørkøy; Terje Johansen
Journal:  Cell Mol Life Sci       Date:  2010-06-25       Impact factor: 9.261

3.  MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells.

Authors:  Qiongyan Zou; Wenjun Yi; Jianghai Huang; Fenfen Fu; Gannong Chen; Dewu Zhong
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

4.  PAX6 overexpression is associated with the poor prognosis of invasive ductal breast cancer.

Authors:  Xianghou Xia; Wenjuan Yin; Xiping Zhang; Xingfei Yu; Chen Wang; Shenhua Xu; Weiliang Feng; Hongjian Yang
Journal:  Oncol Lett       Date:  2015-06-29       Impact factor: 2.967

5.  A common functional regulatory variant at a type 2 diabetes locus upregulates ARAP1 expression in the pancreatic beta cell.

Authors:  Jennifer R Kulzer; Michael L Stitzel; Mario A Morken; Jeroen R Huyghe; Christian Fuchsberger; Johanna Kuusisto; Markku Laakso; Michael Boehnke; Francis S Collins; Karen L Mohlke
Journal:  Am J Hum Genet       Date:  2014-01-16       Impact factor: 11.025

6.  Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.

Authors:  Cheng-Lung Hsu; Jai-Shin Liu; Po-Long Wu; Hong-Hsiang Guan; Yuh-Ling Chen; An-Chi Lin; Huei-Ju Ting; See-Tong Pang; Shauh-Der Yeh; Wen-Lung Ma; Chung-Jung Chen; Wen-Guey Wu; Chawnshang Chang
Journal:  Mol Oncol       Date:  2014-06-24       Impact factor: 6.603

7.  Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.

Authors:  Xiangxian Zhang; Xiao Yang; Junling Wang; Tiansong Liang; Yue Gu; Daoke Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma.

Authors:  Wei-Lun Chang; Wu-Wei Lai; I-Ying Kuo; Chien-Yu Lin; Pei-Jung Lu; Bor-Shyang Sheu; Yi-Ching Wang
Journal:  J Gastroenterol       Date:  2016-09-26       Impact factor: 7.527

9.  PAX6, a novel target of microRNA-7, promotes cellular proliferation and invasion in human colorectal cancer cells.

Authors:  Yanwen Li; Yuehui Li; Yanhong Liu; Pingli Xie; Feng Li; Guancheng Li
Journal:  Dig Dis Sci       Date:  2013-11-02       Impact factor: 3.199

10.  Identification of potential gene signatures associated with osteosarcoma by integrated bioinformatics analysis.

Authors:  Yutao Jia; Yang Liu; Zhihua Han; Rong Tian
Journal:  PeerJ       Date:  2021-05-27       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.